Imaging is perhaps one of the most important tools in an oncologist’s arsenal, supporting diagnosis, prognosis, and longitudinal monitoring of a patient’s response to therapy. In fact, the value of translational methods like magnetic resonance imaging (MRI) and positron emission tomography (PET) extends far beyond the clinic, with many of today’s drug developers utilizing these powerful techniques to advance their preclinical research.
In this webinar, you’ll learn how we’ve used preclinical imaging to document pathological findings like those reported in clinical patients, and how the predictive nature of these translational tools supports your development of new therapies.
Tuulia Huhtala, PhD
Head of Biomarkers and Molecular Imaging, Charles River